Gossamer Bio, Inc. Investigated by the Portnoy Law Firm
Gossamer Bio, Inc. (GOSS)
Last gossamer bio, inc. earnings: 3/24 07:00 am
Check Earnings Report
Company Research
Source: GlobeNewswire
LOS ANGELES, March 18, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Gossamer Bio, Inc. (“Gossamer" or the "Company") (NASDAQ:GOSS) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or join the case via http://portnoylaw.com/gossamer-bio-inc. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses. Gossamer’s stock price plummeted $1.71 per share, or 80.14%, to close at $0.423 per share on February 23, 2026, thereby injuring investors. This massive valuation collapse was triggered by a February 23, 2026, announcement regarding the results of the Phase 3 PROSERA trial. The study was designed to evaluate the efficacy of seralutinib in patients suffering from
Show less
Read more
Impact Snapshot
Event Time:
GOSS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GOSS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GOSS alerts
High impacting Gossamer Bio, Inc. news events
Weekly update
A roundup of the hottest topics
GOSS
News
- Gossamer Bio (GOSS) had its "neutral" rating reaffirmed by Cantor Fitzgerald.MarketBeat
- Biotech company cuts half its staff after disappointing trial sees stock plummet [Yahoo! Finance]Yahoo! Finance
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSSPR Newswire
- GOSS: Management Optimistic About Topline Results -- LEVI & KORSINSKY, LLP Investigates After Trial FailsGlobeNewswire
- GOSS: Management Optimistic About Topline Results -- LEVI & KORSINSKY, LLP Investigates After Trial FailsPR Newswire
GOSS
Earnings
- 3/17/26 - Miss
GOSS
Sec Filings
- 3/24/26 - Form SCHEDULE
- 3/20/26 - Form 4
- 3/20/26 - Form 4
- GOSS's page on the SEC website